Update on frontotemporal dementia

Neurologist

Volumn 16, Issue 1, 2010, Pages 16-22

  Arvanitakis, Zoe ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chromosome 17; Frontotemporal dementia; Primary progressive aphasia; Tau; Ubiquitin

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLUORODEOXYGLUCOSE F 18; GALANTAMINE; MEMANTINE; MOCLOBEMIDE; PACLITAXEL; PAROXETINE; PLACEBO; PROGRANULIN; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; TAU PROTEIN; TRAZODONE; UBIQUITIN;

ALZHEIMER DISEASE; APATHY; BEHAVIOR DISORDER; CHROMOSOME 17; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; DIFFERENTIAL DIAGNOSIS; DRUG MECHANISM; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HUMAN; IMPULSIVENESS; LONG TERM CARE; LOW DRUG DOSE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PATIENT CARE; PRIMARY PROGRESSIVE APHASIA; PRIORITY JOURNAL; REVIEW; SEMANTIC DEMENTIA;

ANIMALS; DIAGNOSIS, DIFFERENTIAL; FRONTOTEMPORAL DEMENTIA; HUMANS; PUBLIC HEALTH; TERMINOLOGY AS TOPIC;

EID: 75749093076     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/NRL.0b013e3181b1d5c6     Document Type: Review

References (75)

1. National Center for Health Statistics, Data Warehouse on Trends in Health and Aging. Available at: http://www. cdc. gov/nchs/agingact. htm.
2. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer disease in a community population of older persons: higher than previously reported. JAMA. 1989;262:2551-2556.
3. Brunnström H, Gustafson L, Passant U, et al. Prevalence of dementia subtypes: a 30-year retrospective survey of neuropathological reports. Arch Gerontol Geriatr. 2009;49:146-149.
4. Schneider JA, Arvanitakis Z, Bang W, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197-2204.
5. Rosso SM, Donker Kaat L, Baks T, et al. Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population- based study. Brain. 2003;126:2016-2022.
6. Hodges JR, Davies R, Xuereb J, et al. Survival in frontotemporal dementia. Neurology. 2003;61:349-354.
7. McKhann GM, Albert MS, Grossman M, et al; Work Group on Frontotemporal Dementia and Pick's Disease. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol. 2001;58:1803-1809.
8. Weintraub S, Rubin NP, Mesulam MM. Primary progressive aphasia. Longitudinal course, neuropsychological profile, and language features. Arch Neurol. 1990;47:1329-1335.
9. Kertesz A, Munoz D. Relationship between frontotemporal dementia and corticobasal degeneration/progressive supranuclear palsy. Dement Geriatr Cogn Disord. 2004;17:282-286.
10. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1994;57:416-418.
11. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-1554.
12. Arvanitakis Z, Graff-Radford N. Focal degenerative dementia syndromes. Clinics Geriatr Med. 2001;17:303-318.
13. Rosen HJ, Allison SC, Ogar JM, et al. Behavioral features in semantic dementia vs. other forms of progressive aphasias. Neurology. 2006;67:1752-1756.
14. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5′-splicesite mutations in tau with the inherited dementia FTDP-17. Nature. 1998; 393:702-705.
15. Dubois B, Slachevsky A, Litvan I, et al. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55:1621-1626.
16. Hodges JR, Martinos M, Woollams AM, et al. Repeat and point: differentiating semantic dementia from progressive non-fluent aphasia. Cortex. 2008; 44:1265-1270.
17. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state. " A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
18. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56: 1143-1153.
19. Gorno-Tempini ML, Brambati SM, Ginex V, et al. The logopenic/phonological variant of primary progressive aphasia. Neurology. 2008;71:1227-1234.
20. Rankin KP, Santos-Modesitt W, Kramer JH, et al. Spontaneous social behaviors discriminate behavioral dementias from psychiatric disorders and other dementias. J Clin Psychiatry. 2008;69:60-73.
21. Heidler-Gary J, Gottesman R, Newhart M, et al. Utility of behavioral versus cognitive measures in differentiating between subtypes of frontotemporal lobar degeneration and Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;23:184-193.
22. Wicklund AH, Rademaker A, Johnson N, et al. Rate of cognitive change measured by neuropsychologic test performance in 3 distinct dementia syndromes. Alzheimer Dis Assoc Disord. 2007;21:S70-S78.
23. Libon DJ, Massimo L, Moore P, et al. Screening for frontotemporal dementias and Alzheimer disease with the Philadelphia Brief Assessment of Cognition: a preliminary analysis. Dement Geriatr Cogn Disord. 2007;24:441-447.
24. Davatzikos C, Resnick SM, Wu X, et al. Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI. Neuroimage. 2008;41:1220-1227.
25. Mendez MF, Shapira JS, McMurtray A, et al. Accuracy of the clinical evaluation for frontotemporal dementia. Arch Neurol. 2007;64:830-835.
26. Diehl-Schmid J, Grimmer T, Drzezga A, et al. Decline in cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET study. Neurobiol Aging. 2007;28:42-50.
27. Foster NL, Wang AY, Tasdizen T, et al. Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer disease. Alzheimer's Dement. 2008;4(suppl 1):S29-S36.
28. Kapaki E, Paraskevas GP, Papageorgiou SG, et al. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2008;22:47-53.
29. Lladó A, Sánchez-Valle R, Rey MJ, et al. Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration. J Neurol. 2008;255:488-494.
30. Grossman M, Libon DJ, Forman MS, et al. Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia. Arch Neurol. 2007;64:1601-1609.
31. Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114:5-22.
32. Spillantini MG, Goedert M, Crowther RA, et al. Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc Natl Acad Sci USA. 1997;94:4113-4118.
33. Knopman DS, Mastri AR, Frey WH II, et al. Dementia lacking distinctive histologic features: a common non-Alzheimer degenerative dementia. Neurology. 1990;40:251-256.
34. Josephs KA, Jones AG, Dickson DW. Hippocampal sclerosis and ubiquitinpositive inclusions in dementia lacking distinctive histopathology. Dement Geriatr Cogn Disord. 2004;17:342-345.
35. Mesulam M, Wicklund A, Johnson N, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol. 2008;63:709-719.
36. Forman MS, Farmer J, Johnson JK, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol. 2006;59:952-962.
37. Ittner LM, Fath T, Ke YD, et al. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci USA. 2008;105:15997-16002
38. Pickering-Brown SM, Rollinson S, Du Plessis D, et al. Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. Brain. 2008;131(pt 3):721-731.
39. Van Deerlin VM, Wood EM, Moore P, et al. Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations. Arch Neurol. 2007;64:1148-1153.
40. Foster NL, Wilhelmsen K, Sima AA, et al. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. Ann Neurol. 1997;41:706-715.
41. Arvanitakis Z, Witte RJ, Dickson DW, et al. Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation). Parkinsonism Relat Disord. 2007;13:230-239.
42. Arvanitakis Z, Wszolek ZK. Recent advances in the understanding of tau protein and movement disorders. Curr Opin Neurol. 2001;14:491-497.
43. Brunden KR, Trojanowski JQ, Lee VM. Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J Alzheimer's Dis. 2008;14:393-399.
44. Baker M, MacKenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442:916-919. (Pubitemid 44285946)
45. Cruts M, Gijselinck I, can Der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442:920-924. (Pubitemid 44285947)
46. Spina S, Murrell JR, Huey ED, et al. Corticobasal syndrome associated with the A9D Progranulin mutation. J Neuropathol Exp Neurol. 2007;66:892-900.
47. Rademakers R, Baker M, Gass J, et al. Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C->T (Arg493X) mutation: an international initiative [erratum in Lancet Neurol. 2007;6:1037]. Lancet Neurol. 2007;6:857-868.
48. Mukherjee O, Wang J, Gitcho M, et al. Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia. Hum Mutat. 2008; 29:512-521.
49. Le Ber I, Camuzat A, Hannequin D, et al. Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain. 2008;131(pt 3):732-746.
50. MacKenzie IR, Baker M, Pickering-Brown S, et al. The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain. 2006;129(pt 11):3081-3090. (Pubitemid 44684527)
51. Zhang YJ, Xu YF, Dickey CA, et al. Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci. 2007;27:10530-10534.
52. Roeber S, Mackenzie IR, Kretzschmar HA, et al. TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD. Acta Neuropathol. 2008;116:147-157.
53. Gydesen S, Brown JM, Brun A, et al. Chromosome 3 linked frontotemporal dementia (FTD-3). Neurology. 2002;59:1585-1594.
54. Holm IE, Englund E, Mackenzie IR, et al. A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. J Neuropathol Exp Neurol. 2007;66:884-891.
55. Kovach MJ, Waggoner B, Leal SM, et al. Clinical delineation and localization to chromosome 9p13. 3-p12 of a unique dominant disorder in four families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal dementia. Mol Genet Metabol. 2001;74:458-475.
56. Watts GD, Thomasova D, Ramdeen SK, et al. Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Clin Genet. 2007;72:420-426.
57. Raux G, Gantier R, Thomas-Anterion C, et al. Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation. Neurology. 2000;55:1577-1578.
58. Boeve BF, Baker M, Dickson DW, et al. Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in programulin: a clinicopathologic study. Brain. 2006;129(pt 11):3103-3114.
59. Swartz JR, Miller BL, Lesser IM, et al. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry. 1997; 58:212-216.
60. Moretti R, Torre P, Antonello RM, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms: a randomized, controlled, open 14-month study. Eur Neurol. 2003;49:13-19.
61. Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacol. 2004;172:400-408.
62. Lebert F, Stekke W, Hasenbroekx C, et al. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17:355-359.
63. Adler G, Teufel M, Drach LM. Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide. Int J Geriatr Psychiatry. 2003;18:653-655.
64. Moretti R, Torre P, Antonello RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21:931-937.
65. Mendez MF, Shapira JS, McMurtray A, et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15:84-87.
66. Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25: 178-185.
67. Diehl-Schmid J, Förstl H, Perneczky R, et al. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry. 2008;23:754-759.
68. Trojanowski JQ, Duff K, Fillit H, et al; Frontotemporal Dementia (FTD) Working Group on FTD Drug Discovery. New directions for frontotemporal dementia drug discovery. Alzheimer's Dement. 2008;4:89-93.
69. Zhang B, Maiti A, Shively S, et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. PNAS USA. 2005;102:227-231.
70. Boxer AL, Boeve BF. Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies. Alzheimer Dis Assoc Disord. 2007;21:S79-S87.
71. Henry ML, Beeson PM, Rapcsak SZ. Treatment for anomia in semantic dementia. Semin Speech Lang. 2008;29:60-70.
72. De Simone V, Kaplan L, Patronas N, et al. Driving abilities in frontotemporal dementia patients. Dement Geriatr Cogn Disord. 2007;23:1-7.
73. Available at: http://www. socialsecurity. gov/compassionateallowances.
74. Rosness TA, Haugen PK, Engedal K. Support to family carers of patients with frontotemporal dementia. Aging Ment Health. 2008;12:462-466.
75. Kaiser S, Panegyres PK. The psychosocial impact of young onset dementia on spouses. Am J Alzheimer's Dis Other Demen. 2006;21:398-402.